Phase II Trial of Lenvatinib Plus PembrolizumAb in Recurrent Gynecological Clear Cell Adenocarcinomas (LARA)
Latest Information Update: 22 Oct 2021
At a glance
- Drugs Lenvatinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Endometrial cancer; Gynaecological cancer; Ovarian cancer
- Focus Therapeutic Use
- Acronyms LARA
- 13 Oct 2021 Status changed from not yet recruiting to recruiting.
- 11 Jan 2021 New trial record